{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/d348aacb-00cd-4b2d-9b3b-ee9d99cdb735/6766c3532dc5d9b993a457ed?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Denmark’s gold rush town","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61ba18761a8cbe923a3cf195/1734787715357-3c8614b6-d07c-46d4-a042-9ed094a035c2.jpeg?height=200","description":"<p>If 2023 was the year weight-loss injections such as Ozempic or WeGovy took over Hollywood, then 2024<em> </em>was the year they went global.&nbsp;What does that mean for Novo Nordisk, the Danish company making them? And can it live up to the hype?</p><p><br></p><p>Writer: Claudia Williams</p><p>Producer: Claudia Williams</p><p>Photography: Joe Mee</p><p>Executive producer: Rebecca Moore</p>","author_name":"The Observer"}